Lausanne University Hospital studies the Anti-HAV Seroprevalence of Travelers or Having Lived in a Tropical Country
Photo by Shivam Kumar
The company University of Lausanne Hospitals is enrolling patients into the clinical trial investigating of the Anti-HAV Seroprevalence of Travelers >60 Years or Having Lived in a Tropical Country for >5 Years (AHAV).
This study is to determine the proportion of travelers over the age of 60 years and travelers having lived in a tropical country for more than 5 years with anti-HAV antibodies. This will be done through a blood test. The investigators will then proceed with a short statistical analysis.
The study start date is October 6, 2019. It is planned to include 200 participants
The primary outcome measure is the percentage of anti-HAV positive tests in the two groups will be calculated.
The patients that can be enrolled into this study include people over 60 years old or travelers that have lived in a tropical country for at least 5 years who consult the travel clinic of Unisanté.
The participants who are younger than 5 years old, have already been vaccinated against hepatitis A and have been injected with immunoglobulins in the past 2 months can not be included.
Hepatitis A is an infectious disease of the liver caused by Hepatovirus A (HAV); it is a type of viral hepatitis. Many cases have few or no symptoms, especially in the young. The time between infection and symptoms, in those who develop them, is between two and six weeks.
It is usually spread by eating food or drinking water contaminated with infected feces. Shellfish which have not been sufficiently cooked are a relatively common source. It may also be spread through close contact with an infectious person. While children often do not have symptoms when infected, they are still able to infect others.After a single infection, a person is immune for the rest of his or her life. Diagnosis requires blood testing, as the symptoms are similar to those of a number of other diseases. It is one of five known hepatitis viruses: A, B, C, D, and E.
This page provides a more detailed overview of this clinical trial:
